FDA removes safety restrictions for Sanofi thyroid cancer drug Sep 25, 2025 02:23PM
FTC Seeks to Block Sanofi’s (SNY) Acquisition of Rare Disease Drug Dec 11, 2023 03:47PM
Sanofi (SNY) Genzyme's Xenpozyme Approved by FDA to Treat Acid Sphingomyelinase Deficiency Aug 31, 2022 01:47PM
Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1 Apr 28, 2022 01:30AM
Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D Feb 4, 2022 01:30AM
View Older Stories

Feb 3, 2022 11:00AM Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity
Oct 28, 2021 01:30AM Sanofi : Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)
Aug 6, 2021 11:45AM Sanofi (SNY) announces FDA approves Nexviazyme, an important new treatment option for late-onset Pompe disease
Aug 6, 2021 11:42AM FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
Jul 29, 2021 01:30AM Sales growth accelerated - Full-year guidance raised
Jun 18, 2021 09:45AM European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
Apr 28, 2021 01:30AM Sanofi poursuit sa trajectoire de croissance. Forte hausse du BNPA des activités(1) au T1 2021 à TCC
Feb 5, 2021 01:30AM T4 2020: Croissance du BNPA des activités(1) de près de 10% à TCC
Oct 29, 2020 02:30AM Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
Sep 9, 2020 07:00AM Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020
Aug 25, 2020 12:42PM Biotechnology Value Fund said Principia Biopharma Inc. (PRNB) proposed sale to Sanofi would be a 'suboptimal and, frankly, sad outcome'
Jul 29, 2020 08:00AM Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
Jul 29, 2020 01:30AM Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
Jun 19, 2020 01:51PM UPDATE: Regeneron (REGN), Sanofi (SNY) Report FDA Approval of Dupixent (dupilumab) Pre-filled Pen Designed to Support More Convenient Self-Administration
Jun 19, 2020 01:51PM FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration
Jun 14, 2020 01:17PM Sobi and Sanofi Donate up to 500 Million Additional IUs of Clotting Factor to WFH Humanitarian Aid Program
Jun 14, 2020 10:58AM Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program
May 29, 2020 01:00AM Sanofi names new leaders to Executive Committee
Apr 24, 2020 07:00AM Sanofi at forefront of fight against COVID-19 in Q1 2020
Apr 24, 2020 01:30AM Sanofi at forefront of fight against COVID-19 in Q1 2020
Apr 17, 2020 01:00AM Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis
Feb 6, 2020 08:00AM Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
Feb 6, 2020 01:30AM Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
Feb 6, 2020 01:30AM Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
Dec 2, 2019 08:31AM Ligand Pharma (LGND) Enters into Worldwide OmniAb Platform License Agreement with Sanofi (SNY)
Nov 6, 2019 09:25AM New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders
Oct 31, 2019 08:05AM Sanofi (SNY) Reports Q3 EPS of EUR1.92
Oct 31, 2019 08:00AM Sanofi Q3 well on track
Oct 31, 2019 02:30AM Sanofi Q3 well on track
Jul 29, 2019 08:00AM Sanofi delivered solid growth in Q2 2019
Jul 29, 2019 05:58AM Sanofi (SNY) Reports Q2 Loss of EUR0.07 on Revenues of EUR8.63B
Jul 29, 2019 01:30AM Sanofi delivered solid growth in Q2 2019
Jun 17, 2019 07:33AM Voyager Therapeutics (VYGR) Reports Restructured Gene Therapy Relationship with Sanofi (SNY) Genzyme; Provides Portfolio Update
Apr 26, 2019 08:05AM Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
Apr 26, 2019 01:31AM Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
Apr 17, 2019 07:00AM World Hemophilia Day: Sanofi Genzyme Donation Impacts Patients Across the Globe
Feb 7, 2019 08:00AM Sanofi delivers 2018 business EPS growth of 5.1% at CER
Feb 7, 2019 01:32AM Sanofi delivers 2018 business EPS growth of 5.1% at CER
Feb 6, 2019 11:53AM FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Feb 6, 2019 11:50AM Sanofi (SNY) announces FDA approval for Cablivi for adults with aTTP
Feb 6, 2019 11:45AM Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Oct 31, 2018 08:00AM Sanofi Q3 2018 Performance Confirms Return to Growth
Oct 31, 2018 02:32AM Sanofi Q3 2018 Performance Confirms Return to Growth
Oct 22, 2018 06:06AM Regeneron (REGN), Sanofi (SNY) Report FDA Approval of Asthma Indication for Dupixent (dupilumab)
Oct 19, 2018 05:59PM Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
Oct 19, 2018 05:55PM FDA approves asthsma indication for Dupixent® (dupilumab)
Sep 28, 2018 04:46PM Regeneron (REGN), Sanofi (SNY) Report Approcal of Libtayo (cemiplimab), the First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Sep 28, 2018 04:41PM Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sep 28, 2018 04:40PM FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sep 13, 2018 06:17AM Sanofi (SNY) Announces Plans to 'Refocus' Two Global Units, Creating a New 'Primary Care' Business Unit and New 'China & Emerging Markets' Business Unit
View Older Stories